Targets › GIPR
14 programs from 11 companies in 147 trials: 54 Phase 3, 40 Phase 2, 29 Phase 4, 24 Phase 1; Metabolic and endocrine, Cardiovascular, Other; next expected readout Nov 2026.
This is a receptor for GIP. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase. (UniProt, P48546)
Open in Phaseline: the race on GIPR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Eli Lilly | Tirzepatide (LY3298176) Gastric inhibitory polypeptide receptor agonist; Glucagon-like peptide 1 receptor agonist | GIPR, GLP1R | Phase 4 | Diabetes Mellitus, Type 2; Psoriatic Arthritis; Type 2 Diabetes; Psoriasis … | Nov 2026 |
| The Cleveland Clinic | GLP-1 or GIP-based therapy GLP-1 receptor agonist and/or GIP receptor agonist | GLP1R, GIPR | Phase 4 | GLP - 1 | – |
| Amgen | Maridebart cafraglutide (AMG 133) GLP-1 receptor agonist and GIP receptor agonist (dual GLP-1/GIP receptor agonist) | GLP1R, GIPR | Phase 3 | Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight; Obesity; Obesity Disease; Obstructive Sleep Apnea … | Nov 2026 |
| Eli Lilly | Retatrutide Glucagon receptor agonist; Glucagon-like peptide 1 receptor agonist; Gastric inhibitory polypeptide receptor agonist | GCGR, GLP1R, GIPR | Phase 3 | Obesity; Type 2 Diabetes; Diabetes Mellitus, Type 2; Atherosclerotic Cardiovascular Disease (ASCVD) … | Nov 2026 |
| Pfizer | Berobenatide (PF-08653944, MET097) Dual GLP-1R/GIPR agonist | GIPR, GLP1R | Phase 3 | Obesity and Overweight; Obesity; Apnea; Overweight … | Jan 2027 |
| Roche | Enicepatide (RO7795068) Dual GLP-1/GIP receptor agonist | GLP1R, GIPR | Phase 3 | Obesity; Obesity or Overweight; Healthy Participants | Apr 2027 |
| Viking Therapeutics | VK2735 GLP-1 and GIP dual agonist | GLP1R, GIPR | Phase 3 | Weight Loss; Obese Adults | May 2027 |
| Novo Nordisk | Zenagamtide GLP-1/GIP receptor agonist | GLP1R, GIPR | Phase 3 | Overweight; Type 2 Diabetes | Jun 2028 |
| The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Mazdutide (IBI362) Triple GLP-1/GIP/glucagon receptor agonist | GLP1R, GIPR, GCGR | Phase 3 | Dementia, Mild | Aug 2029 |
| Regeneron Pharmaceuticals | Olatorepatide (HS-20094) GLP-1 and GIP receptor agonist | GLP1R, GIPR | Phase 2 | Overweight or Obesity | Nov 2026 |
| Roche | RO7795081 GLP-1/GIP receptor dual agonist | GIPR, GLP1R | Phase 2 | Type 2 Diabetes Mellitus; Overweight; Healthy Volunteers; Renal Impairment | Dec 2026 |
| Hudson Biotech | Retatrutide (LY3437943) Glucagon receptor agonist; Glucagon-like peptide 1 receptor agonist; Gastric inhibitory polypeptide receptor agonist | GCGR, GLP1R, GIPR | Phase 2 | Obesity | Mar 2027 |
| Vanderbilt University Medical Center | GIP(3-30)NH2 GIP receptor antagonist | GIPR | Phase 2 | Postural Tachycardia Syndrome (POTS) | May 2027 |
| Novo Nordisk | NNC0480-0389 GIP receptor agonist | GIPR | Phase 1 | Overweight | Jan 2027 |
Obesity (41) Overweight (10) Diabetes Mellitus, Type 2 (5) Type 2 Diabetes (4) Obesity and Obesity-related Medical Conditions (4) Obesity or Overweight (3) Type 2 Diabetes Mellitus (3) Type 1 Diabetes (3) Overweight or Obesity (2) Metabolic Dysfunction-Associated Steatotic Liver Disease (2) Apnea (2) Obesity (Disorder) (2)
protein or peptide (9), small molecule (4), mixed (1)
Eli Lilly (2) Roche (2) Novo Nordisk (2) Amgen (1) Regeneron Pharmaceuticals (1) Pfizer (1) The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (1) The Cleveland Clinic (1) Viking Therapeutics (1) Vanderbilt University Medical Center (1) Hudson Biotech (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.